BioLife Solutions Inc (NASDAQ:BLFS) CEO Sells $178,983.35 in Stock

BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 9,905 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $18.07, for a total value of $178,983.35. Following the completion of the sale, the chief executive officer now owns 184,919 shares in the company, valued at approximately $3,341,486.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Rice also recently made the following trade(s):

  • On Tuesday, August 13th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.07, for a total value of $153,630.00.
  • On Tuesday, July 16th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.29, for a total value of $146,610.00.
  • On Thursday, July 18th, Michael Rice sold 18,903 shares of BioLife Solutions stock. The stock was sold at an average price of $16.29, for a total value of $307,929.87.
  • On Tuesday, June 11th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.64, for a total value of $158,760.00.
  • On Thursday, June 13th, Michael Rice sold 18,903 shares of BioLife Solutions stock. The stock was sold at an average price of $17.37, for a total value of $328,345.11.

BLFS stock traded up $0.42 during mid-day trading on Monday, reaching $20.20. 187,400 shares of the company’s stock were exchanged, compared to its average volume of 175,530. The company has a market cap of $396.72 million, a price-to-earnings ratio of 144.29 and a beta of 1.37. The stock’s 50 day moving average is $17.80 and its 200 day moving average is $17.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.42 and a quick ratio of 12.99. BioLife Solutions Inc has a 12-month low of $9.15 and a 12-month high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.59 million. BioLife Solutions had a return on equity of 8.65% and a net margin of 14.60%. On average, research analysts forecast that BioLife Solutions Inc will post 0.1 earnings per share for the current fiscal year.

A number of analysts have recently commented on the company. Zacks Investment Research downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Maxim Group set a $24.00 target price on BioLife Solutions and gave the stock a “buy” rating in a research note on Friday, August 9th. ValuEngine downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Northland Securities restated a “buy” rating and issued a $18.00 target price on shares of BioLife Solutions in a research note on Tuesday, July 9th. Finally, BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $18.67.

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in BioLife Solutions by 2.0% during the second quarter. Vanguard Group Inc. now owns 627,183 shares of the medical equipment provider’s stock worth $10,631,000 after purchasing an additional 12,416 shares in the last quarter. BlackRock Inc. boosted its position in BioLife Solutions by 129.3% during the second quarter. BlackRock Inc. now owns 541,305 shares of the medical equipment provider’s stock worth $9,177,000 after purchasing an additional 305,276 shares in the last quarter. Russell Investments Group Ltd. boosted its position in BioLife Solutions by 230.8% during the second quarter. Russell Investments Group Ltd. now owns 299,240 shares of the medical equipment provider’s stock worth $5,067,000 after purchasing an additional 208,786 shares in the last quarter. Allianz Asset Management GmbH boosted its position in BioLife Solutions by 7.4% during the second quarter. Allianz Asset Management GmbH now owns 215,449 shares of the medical equipment provider’s stock worth $3,652,000 after purchasing an additional 14,779 shares in the last quarter. Finally, Cadence Capital Management LLC boosted its position in BioLife Solutions by 1.8% during the first quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock worth $3,493,000 after purchasing an additional 3,439 shares in the last quarter. Institutional investors own 47.86% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Read More: What is Cost of Capital?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.